Keyword: rare diseases

27 results found

The 10 highest-cost drugs reimbursed by public drug plans in Canada in the 2021/22 fiscal year were all rare disease treatments with annual treatment costs of more than $250,000, according to a new report by the Patented Medicine Prices Review Board. It found the increased use of high-cost drugs continued to be the main factor […]

Copyright_jovannig_123RF

The federal government is appointing members to an implementation advisory group to support the launch of its national strategy for drugs for rare diseases. The members from Canada’s private payer community include: Stephen Frank, president and chief executive officer of the Canadian Life and Health Insurance Association; Joanne Jung, Canadian pharmacy and clinical practice leader at […]

  • By: Staff
  • November 3, 2023 November 7, 2023
  • 09:00
Copyright_irinkavasilinka_123RF

Three-fifths (60 per cent) of benefits plan sponsors say the costs of their health benefits plan increased in the past three years, according to the 2023 Benefits Canada Healthcare Survey. It found this percentage decreased from 66 per cent when the question was last asked in 2016 and was unchanged from 2015 (60 per cent). […]

  • By: Staff
  • September 25, 2023 September 22, 2023
  • 09:00

A recent report by the Patented Medicine Prices Review Board shows increased growth for private drug plan costs but promising pharmaceutical innovation, says Joe Farago, executive director of private payers and investment at Innovative Medicines Canada. The report also found the number of new medicines launched in Canada was higher than the median for Organisation for […]

  • By: Sadie Janes
  • September 20, 2023 September 20, 2023
  • 09:00
Copyright_Wavebreak Media Ltd_123RF

By focusing on cancer as part of a wider chronic disease management strategy, employers can support employee health while reducing benefits costs, said Chris Bonnett, founder and principal at H3 Consulting, during a webinar hosted by the Canadian Pension and Benefits Institute. While long-term disability plans pay out, on average, $3,500 per month, cancer patients […]

As the coronavirus pandemic enters its fourth year, it’s perhaps unsurprising that the health crisis has taken its toll on employee mental health. Scotiabank saw a notable rise in claims for mental-health drugs in 2022, says Ayman Alvi, the bank’s vice-president of global pension and benefits, noting the increased use of these medications aligns with […]

Running for more than 17 years, Benefits Canada‘s Face to Face Drug Plan Management Forum is the industry’s most popular drug benefits conference. In 2022, the event returned to a face-to-face format at the Sheraton Centre in Toronto on Dec. 6. Attendees learned about fresh drug plan design insights, including a new drug launch panel […]

About a million Canadians are impacted by rare diseases, which disproportionately affect younger patients — 70 per cent start in childhood and, sadly, half of these children won’t reach adulthood, said Suzanne Lepage, a private health plan strategist, during a session supported by Alexion Pharmaceuticals at Benefits Canada‘s 2022 Face to Face Drug Plan Management Forum […]

Living with a rare chronic disease while also managing an employer-sponsored benefits plan provides Chris MacLeod with a unique perspective. During a session supported by Vertex Pharmaceuticals at Benefits Canada’s 2022 Face to Face Drug Plan Management Forum in Toronto in December, MacLeod, the founding partner at Cambridge LLP, said he was diagnosed with cystic fibrosis […]

Copyright_ilixe48_123RF

An article on the strike by Ontario education workers was the most-read story on BenefitsCanada.com over the last week. Here are the five most popular news stories of the week: 1. CUPE’s Ontario education workers striking for extended benefits, wage increases 2. Stellantis, Unifor agreement includes pension and retirement gains 3. Sounding Board: How employers can better support employees […]

  • By: Staff
  • November 11, 2022 November 11, 2022
  • 09:00